BACKGROUND: Participants in the multi-center, randomized Total or Supracervical Hysterectomy (TOSH) trial showed within-group improvement in pelvic floor symptoms 2 years post-surgery and no differences between supracervical (SCH) versus total hysterectomy (TAH). This study describes longer term outcomes from the largest recruiting site. STUDY DESIGN:Questionnaires addressing pelvic symptoms, sexual function, and health-related quality of life were administered. Linear models and McNemar's test were utilized. RESULTS:Thirty-seven participants (69%) responded (19 TAH, 18 SCH); mean follow up was 9.1±0.7 years. No between-group differences emerged in urinary incontinence, voiding dysfunction, pelvic prolapse symptoms and overall health related quality of life (HRQOL). Within-group analysis showed significant improvement in the ability to have and enjoy sex (P = 0.002) and in the SF-36 physical component summary score (P = 0.03) among women randomized to TAH. CONCLUSION: 9 years after surgery, TOSH participants continue to experience improvement and show no major between-group differences in lower urinary tract or pelvic floor symptoms conferring no major benefit of SCH over TAH.
RCT Entities:
BACKGROUND:Participants in the multi-center, randomized Total or Supracervical Hysterectomy (TOSH) trial showed within-group improvement in pelvic floor symptoms 2 years post-surgery and no differences between supracervical (SCH) versus total hysterectomy (TAH). This study describes longer term outcomes from the largest recruiting site. STUDY DESIGN: Questionnaires addressing pelvic symptoms, sexual function, and health-related quality of life were administered. Linear models and McNemar's test were utilized. RESULTS: Thirty-seven participants (69%) responded (19 TAH, 18 SCH); mean follow up was 9.1±0.7 years. No between-group differences emerged in urinary incontinence, voiding dysfunction, pelvic prolapse symptoms and overall health related quality of life (HRQOL). Within-group analysis showed significant improvement in the ability to have and enjoy sex (P = 0.002) and in the SF-36 physical component summary score (P = 0.03) among women randomized to TAH. CONCLUSION: 9 years after surgery, TOSH participants continue to experience improvement and show no major between-group differences in lower urinary tract or pelvic floor symptoms conferring no major benefit of SCH over TAH.
Authors: Miriam Kuppermann; Robert L Summitt; R Edward Varner; S Gene McNeeley; Deborah Goodman-Gruen; Lee A Learman; Christine C Ireland; Eric Vittinghoff; Feng Lin; Holly E Richter; Jonathan Showstack; Stephen B Hulley; A Eugene Washington Journal: Obstet Gynecol Date: 2005-06 Impact factor: 7.661
Authors: M Morelli; R Noia; D Chiodo; R Mocciaro; A Costantino; M T Caruso; C Cosco; E Lucia; B Curcio; G Gullì; G Amendola; F Zullo Journal: Minerva Ginecol Date: 2007-02
Authors: Lee A Learman; Robert L Summitt; R Edward Varner; S Gene McNeeley; Deborah Goodman-Gruen; Holly E Richter; Feng Lin; Jonathan Showstack; Christine C Ireland; Eric Vittinghoff; Stephen B Hulley; A Eugene Washington Journal: Obstet Gynecol Date: 2003-09 Impact factor: 7.661
Authors: A L Stewart; S Greenfield; R D Hays; K Wells; W H Rogers; S D Berry; E A McGlynn; J E Ware Journal: JAMA Date: 1989-08-18 Impact factor: 56.272
Authors: Gabriel Francisco Aleixo; Marcelo C M Fonseca; Maria Augusta Tezelli Bortolini; Luiz Gustavo O Brito; Rodrigo A Castro Journal: Int Urogynecol J Date: 2018-11-22 Impact factor: 2.894
Authors: Zeinab Kassem; Chad M Coleman; Andrew S Bossick; Wan-Ting Su; Roopina Sangha; Ganesa Wegienka Journal: J Patient Cent Res Rev Date: 2019-01-28